A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting specific signalling pathways, have been joined by cellular immunotherapies based on T cell engineering. The rapid adoption of novel, patient-specific cellular therapies builds...

Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Tsokanas

A study using lithium for epithelial regeneration in acute GvHD was presented. Presenter:Dr Liga  Participants:Prof.Spyridonidis, Dr Tsokanas

Rates of CLABSI are the same in internal jugular vein-and subclavian vein-CVC after allogeneic HCTThe strongest risk factor for local inflammation or fever are >6 neutropenic CVC-days·Time to local inflammation is longer with CVC placed in the internal jugular vein·CVC placed in the subclavian...

Real-life experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO). Efficacy and safety of nivolumab in real-life for the treatment of R/R Hodgkin lymphoma is comparable with that reported in clinical trials.·The main reasons for nivolumab discontinuation were referral for transplantation and disease...

In a cohort of 126 allogeneic HCT recipients transplanted 1-39 years ago,62% were seropositive/seroprotected for measles before any vaccination since transplantation. The seropositivity/seroprotection was associated with myeloproliferative disorder, reduced intensity or non-myeloablative conditioning and absence of acute grade>2 graft-versus-host disease.·Our findings strongly support a systematic assessment...

Presenter: Dr Liga, Participants: Prof.Spyridonidis, Dr Tsokanas, Dr Lekka, Dr Bali

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali

A review on a very common complication in our patients. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali

Which aml sr pts benefit from transplant. Another role of mrd. https://pubmed.ncbi.nlm.nih.gov/29601212/?dopt=Abstract Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali

https://pubmed.ncbi.nlm.nih.gov/33897681/ Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali

https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2020010543/476241/CAR-HEMATOTOX-A-model-for-CAR-T-cell-related?redirectedFrom=fulltext Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali

With a limited follow-up, the German experience (203 pts) with SOC CAR-T cells in LBCL is in keeping with the approval trials in terms of safety, whereas our efficacy data appear to be inferior to published results. ABSTRACT EBMT AA2-2 STANDARD-OF-CARE CAR-T CELL THERAPY FOR LARGE B-CELL LYMPHOMA: REAL WORLD...

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka